Clinical Trial Update: Pycnogenol® in Post-COVID-19 Condition [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Pycnogenol for post-COVID-19 condition (long COVID) is listed as active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Pycnogenol (French maritime pine bark extract (Pinus pinaster bark extract))

Snippet

Sponsor: University of Zurich | Conditions: Post COVID-19 Condition, Long COVID | Phase 3 | Status: ACTIVE_NOT_RECRUITING